Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary imaging response to once-daily FF/UMEC/VI in eosinophilic asthma
ISRCTN18210817Phase 3Completed
- Sponsor
- Western University
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluticasone in asthma and eosinophilic asthma (EA), sponsored by Western University. Primary endpoint: Ventilation defect percent at Visit 2. Started Aug 2022; status: completed.
02
Drugs
fluticasone
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on ISRCTN18210817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18210817.